Skip to main
LMAT
LMAT logo

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc. demonstrated a strong financial performance in the second quarter of 2025, with a gross margin increase of 110 basis points to 70.0%, attributed to higher average selling prices (ASPs) and improved manufacturing efficiencies. The company reported a 15% increase in revenue on both an as-reported and organic basis, supported by substantial year-over-year growth across all geographic segments: a 12% increase in the Americas, a 23% increase in EMEA, and a 12% increase in APAC sales. Additionally, the positive outlook is reinforced by an upward revision of the calendar year 2025 revenue estimate to $252.6 million, reflecting a robust performance in Q2 and enhancements in the salesforce's efficiency.

Bears say

LeMaitre Vascular Inc. faces a negative outlook due to a revision in its sales force target for FY/25, decreasing from 170 to 165 representatives, indicating potential challenges in future sales growth. Furthermore, the company's inability to maintain or increase selling prices may lead to reduced sales growth and negatively impact operating results. Lastly, the significant decline of approximately 17% year-over-year in research and development expenses to $3.5 million raises concerns about the firm's commitment to innovation and long-term growth prospects.

LeMaitre Vascular (LMAT) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 6 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.